AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7418949 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanabenz (24 mg daily)
Number of subjects: 168
Study 7418949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 30933948 — intervention group
Group type: EXPERIMENTAL
Intervention: Connective Tissue Manipulation Group (CTMG)
Number of subjects: 210
Study 30933948 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 210
Study 28732519 — intervention group
Group type: EXPERIMENTAL
Intervention: General skin-care advice plus emollients applied daily for the first year of life
Number of subjects: 1400
Study 28732519 — intervention group
Group type: COMPARATOR
Intervention: General infant skin-care advice
Number of subjects: 1400
Study 24916884 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity (HI, 74% of 1‐repetition maximum)
Number of subjects: 10
Study 24916884 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle-intensity (MI, 54% 1RM)
Number of subjects: 10
Study 24916884 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle-intensity no-relaxation exercise (MIR, 54% 1RM)
Number of subjects: 10
Study 23223921 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdebrider-assisted inferior turbinoplasty (MAIT)
Number of subjects: 35
Study 23223921 — intervention group
Group type: COMPARATOR
Intervention: Partial turbinectomy
Number of subjects: 35
Study 23223921 — intervention group
Group type: COMPARATOR
Intervention: Electrocautery
Number of subjects: 35
Study 21226886 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence-contingent employment
Number of subjects: 51
Study 21226886 — intervention group
Group type: COMPARATOR
Intervention: Control (independent of drug use)
Number of subjects: 51
Study 19521351 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide/metreleptin (360 microg/5 mg b.i.d.)
Number of subjects: 177
Study 19521351 — intervention group
Group type: COMPARATOR
Intervention: Pramlintide (360 microg b.i.d.)
Number of subjects: 177
Study 19521351 — intervention group
Group type: COMPARATOR
Intervention: Metreleptin (5 mg b.i.d.)
Number of subjects: 177
Study 17845277 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine/fluoxetine combination
Number of subjects: 833
Study 17845277 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 833
Study 14984857 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 10 microg.kg(‐1)
Number of subjects: 82
Study 14984857 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 20 microg.kg(‐1)
Number of subjects: 82
Study 14984857 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 40 microg.kg(‐1)
Number of subjects: 82
Study 14984857 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 80 microg.kg(‐1)
Number of subjects: 82
Study 14984857 — intervention group
Group type: COMPARATOR
Intervention: Control (no droperidol)
Number of subjects: 82
Study 11491418 — intervention group
Group type: COMPARATOR
Intervention: Combivir
Number of subjects: 75
Study 11491418 — intervention group
Group type: EXPERIMENTAL
Intervention: Combivir plus abacavir
Number of subjects: 75
Study 10067662 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (0.28 micromole/kg bw/minute)
Number of subjects: 35
Study 10067662 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 35
Study 7622258 — intervention group
Group type: EXPERIMENTAL
Intervention: Dicloxacillin (0.5 g, 0.75 g, or 1.0 g)
Number of subjects: 12
Study 7622258 — intervention group
Group type: COMPARATOR
Intervention: Flucloxacillin (0.75 g)
Number of subjects: 12
Study 7622258 — intervention group
Group type: EXPERIMENTAL
Intervention: Flucloxacillin
Number of subjects: 12
Study 7622258 — intervention group
Group type: EXPERIMENTAL
Intervention: Dicloxacillin
Number of subjects: 12
Study 7622258 — intervention group
Group type: EXPERIMENTAL
Intervention: Dicloxacillin and Flucloxacillin
Number of subjects: 12
Study 2239935 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (r‐HuEPO)
Number of subjects: 22
Study 2239935 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 22
Study 321005 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 61
Study 321005 — intervention group
Group type: COMPARATOR
Intervention: Parenteral penicillin
Number of subjects: 61
Study 321005 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacteriological studies
Number of subjects: 61
Study 31228534 — intervention group
Group type: EXPERIMENTAL
Intervention: Prioritizing extending life
Number of subjects: 535
Study 31228534 — intervention group
Group type: EXPERIMENTAL
Intervention: Prioritizing relief of discomfort
Number of subjects: 535
Study 31228534 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsure of prioritized value
Number of subjects: 535
Study 31228534 — intervention group
Group type: EXPERIMENTAL
Intervention: Older patients prioritizing relief of discomfort
Number of subjects: 535
Study 31228534 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with better self-perceived health prioritizing relief of discomfort
Number of subjects: 535
Study 29202549 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.5 to 2.0 mg orally)
Number of subjects: 45
Study 25245427 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilevel modeling approach for analyzing accelerometer data
Number of subjects: 0
Study 25245427 — intervention group
Group type: COMPARATOR
Intervention: Traditional methods for analyzing accelerometer data
Number of subjects: 0
Study 23612508 — intervention group
Group type: EXPERIMENTAL
Intervention: ADF-HF diet
Number of subjects: 35
Study 23612508 — intervention group
Group type: COMPARATOR
Intervention: ADF-LF diet
Number of subjects: 35
Study 21375545 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile perfusion (PP)
Number of subjects: 40
Study 21375545 — intervention group
Group type: COMPARATOR
Intervention: Nonpulsatile perfusion (NP)
Number of subjects: 40
Study 19596415 — intervention group
Group type: EXPERIMENTAL
Intervention: H5N1 inactivated subvirion vaccine
Number of subjects: 35
Study 19596415 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm-predicted epitopes
Number of subjects: 35
Study 19596415 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual HA peptides identified from the library
Number of subjects: 35
Study 17006875 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg immediately following surgery and every 24 h for a further three days
Number of subjects: 33
Study 17006875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 14747125 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucocyte-depleting (LD) arterial line filter
Number of subjects: 192
Study 14747125 — intervention group
Group type: COMPARATOR
Intervention: Avecor Affinity or Pall Autovent-6 control filter
Number of subjects: 192
Study 11268298 — intervention group
Group type: COMPARATOR
Intervention: Hormone-based therapies (progestins, androgens, GnRH analogs)
Number of subjects: 0
Study 11268298 — intervention group
Group type: COMPARATOR
Intervention: Surgical therapy (hysterectomy with oophorectomy or organ-sparing surgery)
Number of subjects: 0
Study 9710338 — intervention group
Group type: EXPERIMENTAL
Intervention: Probe-tube microphone measurements of insertion gain
Number of subjects: 0
Study 9710338 — intervention group
Group type: COMPARATOR
Intervention: Sound field threshold measurements
Number of subjects: 0
Study 8721471 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure bands on the P-6 acupoint
Number of subjects: 60
Study 8721471 — intervention group
Group type: COMPARATOR
Intervention: Placebo bands on the P-6 acupoint
Number of subjects: 60
Study 2688036 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 600 mg three times a day
Number of subjects: 17
Study 2688036 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 4940876 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclacillin
Number of subjects: 0
Study 4940876 — intervention group
Group type: COMPARATOR
Intervention: Penicillin G
Number of subjects: 0
Study 30640504 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart Choices 4 Teens (experimental condition)
Number of subjects: 411
Study 28603046 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxycamptothecin (HCPT)
Number of subjects: 0
Study 26960500 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg PO OD) as second-line treatment
Number of subjects: 23
Study 24187287 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm support (AS) training device
Number of subjects: 0
Study 24187287 — intervention group
Group type: COMPARATOR
Intervention: Conventional reach training (CON)
Number of subjects: 0
Study 22111771 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellofemoral arthroplasty
Number of subjects: 0
Study 22111771 — intervention group
Group type: COMPARATOR
Intervention: Total knee arthroplasty
Number of subjects: 0
Study 22111771 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 0
Study 19487905 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir (DRV/r) 800/100 mg once daily
Number of subjects: 689
Study 19487905 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/ritonavir (LPV/r) 800/200 mg total daily dose
Number of subjects: 689
Study 16469156 — intervention group
Group type: EXPERIMENTAL
Intervention: LKFibre diet
Number of subjects: 38
Study 15349011 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg/d for 18 days
Number of subjects: 20
Study 11421518 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance muscle strength training
Number of subjects: 19
Study 9252930 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervex-Brush
Number of subjects: 213
Study 9252930 — intervention group
Group type: COMPARATOR
Intervention: Spatula plus Cytobrush (S+C)
Number of subjects: 213
Study 8501340 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofazimine 50 mg daily
Number of subjects: 110
Study 8501340 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 110
Study 8501340 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 110
Study 2443619 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) 450 mg/m2 IV bolus daily for five days, then 200 mg/m2 IV bolus every other day for six doses
Number of subjects: 74
Study 2443619 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 50 mg/m2 IV infusion over four hours followed by IV bolus of 5-FU 600 mg/m2 weekly for 4 weeks and then every 2 weeks
Number of subjects: 74
Study 2443619 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucovorin 500 mg/m2 IV infusion with 5-FU 600 mg/m2 IV bolus one hour after Leucovorin every week for 6 weeks
Number of subjects: 74
Study 2443619 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU) alone
Number of subjects: 74
Study 2443619 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU) and methotrexate (MTX)
Number of subjects: 74
Study 31734098 — intervention group
Group type: EXPERIMENTAL
Intervention: nalbuphine 0.08 mg/kg
Number of subjects: 60
Study 31734098 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 8 mg
Number of subjects: 60
Study 31734098 — intervention group
Group type: COMPARATOR
Intervention: normal saline (control)
Number of subjects: 60
Study 30481183 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological advocacy (SPA) sessions (8 sessions with 2 follow-up sessions)
Number of subjects: 263
Study 30481183 — intervention group
Group type: COMPARATOR
Intervention: Normal DVA advocacy (control group)
Number of subjects: 263
Study 28263399 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflective-behavioral gratitude journal
Number of subjects: 192
Study 28263399 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflective gratitude journal
Number of subjects: 192
Study 28263399 — intervention group
Group type: COMPARATOR
Intervention: Active control journal
Number of subjects: 192
Study 25150557 — intervention group
Group type: EXPERIMENTAL
Intervention: Barthel Index assessment
Number of subjects: 878
Study 25150557 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional judgment of nursing care needs
Number of subjects: 878
Study 23290580 — intervention group
Group type: EXPERIMENTAL
Intervention: Full model (considering both misclassification and missing data)
Number of subjects: 0
Study 23290580 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative models (considering only misclassification or only missing data)
Number of subjects: 0
Study 23290580 — intervention group
Group type: COMPARATOR
Intervention: Naïve model (ignoring both sources of bias)
Number of subjects: 0
Study 21885490 — intervention group
Group type: EXPERIMENTAL
Intervention: VLD cyclobenzaprine (CBP) 1-4 mg at bedtime
Number of subjects: 36
Study 21885490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 19546753 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic surgery
Number of subjects: 300
Study 19546753 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 300
Study 16936208 — intervention group
Group type: EXPERIMENTAL
Intervention: T-cell proliferative assay
Number of subjects: 62
Study 16936208 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoblot assay
Number of subjects: 62
Study 16936208 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoantibody assay
Number of subjects: 62
Study 16936208 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cellular assays and autoantibody measurements
Number of subjects: 62
Study 12921194 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adults (aged 55 and over)
Number of subjects: 1204
Study 12921194 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle-aged adults (aged 40 to 54)
Number of subjects: 1204
Study 12921194 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger adults (aged 18-39)
Number of subjects: 1204
Study 10720126 — intervention group
Group type: EXPERIMENTAL
Intervention: Third intensification block at week 35
Number of subjects: 1781
Study 10720126 — intervention group
Group type: COMPARATOR
Intervention: No third intensification block
Number of subjects: 1781
Study 10720126 — intervention group
Group type: EXPERIMENTAL
Intervention: Third intensification block
Number of subjects: 1781
Study 10720126 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 1781
Study 9360512 — intervention group
Group type: EXPERIMENTAL
Intervention: [norleucine27]GHRH (1-29)-NH2 at a dose of 10 micrograms/kg
Number of subjects: 19
Study 9360512 — intervention group
Group type: EXPERIMENTAL
Intervention: [norleucine27]GHRH (1-29)-NH2
Number of subjects: 19
Study 8255636 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 15
Study 8255636 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Cromoglycate (SCG)
Number of subjects: 15
Study 8255636 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 15
Study 3834842 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (weekly malaria chemoprophylaxis)
Number of subjects: 198
Study 3834842 — intervention group
Group type: COMPARATOR
Intervention: Control (age-matched children without chloroquine)
Number of subjects: 198
Study 3834842 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with malaria parasitaemia
Number of subjects: 198
Study 3834842 — intervention group
Group type: COMPARATOR
Intervention: Children without malaria parasitaemia
Number of subjects: 198
Study 30357256 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tidal volume ventilation (n = 477)
Number of subjects: 961
Study 30357256 — intervention group
Group type: COMPARATOR
Intervention: Intermediate tidal volume ventilation (n = 484)
Number of subjects: 961
Study 26762727 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation in patients with STS <7%
Number of subjects: 996
Study 26762727 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation in patients with STS <7% with moderate/severe aortic regurgitation (AR) at discharge
Number of subjects: 996
Study 26762727 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation in patients with STS >7% with moderate/severe aortic regurgitation (AR) at discharge
Number of subjects: 996
Study 26762727 — intervention group
Group type: COMPARATOR
Intervention: Transcatheter aortic valve implantation in both STS <7% and STS >7% groups
Number of subjects: 996
Study 25170226 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg/d PI-88
Number of subjects: 143
Study 25170226 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg/d PI-88
Number of subjects: 143
Study 25170226 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 143
Study 22576717 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentored learning (lecture and coaching)
Number of subjects: 16
Study 22576717 — intervention group
Group type: COMPARATOR
Intervention: Self-directed learning (no mentoring)
Number of subjects: 16
Study 22576717 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentored learning (4 months later)
Number of subjects: 16
Study 22576717 — intervention group
Group type: COMPARATOR
Intervention: Self-directed learning (4 months later)
Number of subjects: 16
Study 20719465 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin (0.75 mg/kg intravenous bolus and intraprocedural infusion at 1.75 mg/kg/h)
Number of subjects: 220
Study 20719465 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (100 UI/kg)
Number of subjects: 220
Study 18308431 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-GI diet
Number of subjects: 32
Study 18308431 — intervention group
Group type: COMPARATOR
Intervention: Higher-GI diet
Number of subjects: 32
Study 15977006 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary fixation with a titanium pin (surgical intervention)
Number of subjects: 27
Study 15977006 — intervention group
Group type: COMPARATOR
Intervention: Rucksack bandage (nonoperative treatment)
Number of subjects: 27
Study 12452023 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel and carboplatin regimen (PC)
Number of subjects: 68
Study 12452023 — intervention group
Group type: COMPARATOR
Intervention: Ifosfamide, etoposide, and carboplatin regimen (IEC)
Number of subjects: 68
Study 10360907 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled ovarian hyperstimulation (COH)
Number of subjects: 35
Study 10360907 — intervention group
Group type: COMPARATOR
Intervention: Ovulatory controls
Number of subjects: 35
Study 7497366 — intervention group
Group type: COMPARATOR
Intervention: Dynamic Hip Screw (DHS)
Number of subjects: 101
Study 7497366 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma Nail (GN)
Number of subjects: 101
Study 1779009 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimates made by nurses
Number of subjects: 57
Study 1779009 — intervention group
Group type: COMPARATOR
Intervention: Estimates made by physicians
Number of subjects: 57
Study 1779009 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized burn forms
Number of subjects: 57
Study 1779009 — intervention group
Group type: EXPERIMENTAL
Intervention: Methods used for estimating burn size
Number of subjects: 57
Study 7035637 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-P
Number of subjects: 71
Study 7035637 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP
Number of subjects: 71
Study 7035637 — intervention group
Group type: COMPARATOR
Intervention: DTP
Number of subjects: 71
Study 30457029 — intervention group
Group type: COMPARATOR
Intervention: Conventional ultrasound device
Number of subjects: 20
Study 30457029 — intervention group
Group type: EXPERIMENTAL
Intervention: Pocket-sized ultrasound
Number of subjects: 20
Study 28544150 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐ADM (single application)
Number of subjects: 168
Study 28544150 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐ADM (all applications)
Number of subjects: 168
Study 28544150 — intervention group
Group type: COMPARATOR
Intervention: GJ‐ADM
Number of subjects: 168
Study 28544150 — intervention group
Group type: EXPERIMENTAL
Intervention: GJ‐ADM (single application)
Number of subjects: 168
Study 28544150 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐ADM
Number of subjects: 168
Study 25985038 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% lignocaine HCl and 0.1% epinephrine HCl with iontophoretic current of 120 μA for 90s
Number of subjects: 13
Study 25985038 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine solution (control)
Number of subjects: 13
Study 24039234 — intervention group
Group type: EXPERIMENTAL
Intervention: BPS management (antibiotic indication with a BPS ≥ 4 points)
Number of subjects: 120
Study 24039234 — intervention group
Group type: COMPARATOR
Intervention: Routine management (antibiotic indication based on institutional guidelines)
Number of subjects: 120
Study 24039234 — intervention group
Group type: EXPERIMENTAL
Intervention: BPS management
Number of subjects: 120
Study 24039234 — intervention group
Group type: COMPARATOR
Intervention: Routine management
Number of subjects: 120
Study 22461445 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric training program (3 sessions/week; 3-5 sets of 10 repetitions with loads between 40-50% of maximal isometric voluntary contraction)
Number of subjects: 20
Study 22461445 — intervention group
Group type: COMPARATOR
Intervention: Acute eccentric exercise (first bout)
Number of subjects: 20
Study 22461445 — intervention group
Group type: COMPARATOR
Intervention: Acute eccentric exercise (second bout after training)
Number of subjects: 20
Study 19407468 — intervention group
Group type: EXPERIMENTAL
Intervention: Wipe A
Number of subjects: 130
Study 19407468 — intervention group
Group type: EXPERIMENTAL
Intervention: Wipe B
Number of subjects: 130
Study 19407468 — intervention group
Group type: COMPARATOR
Intervention: Cloth and water (control)
Number of subjects: 130
Study 17304686 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (PR)
Number of subjects: 24
Study 16094064 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (desmopressin plus oxybutynin)
Number of subjects: 145
Study 16094064 — intervention group
Group type: COMPARATOR
Intervention: Desmopressin alone
Number of subjects: 145
Study 16094064 — intervention group
Group type: COMPARATOR
Intervention: Imipramine alone
Number of subjects: 145
Study 12526285 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.2 mg) once daily for 24 weeks
Number of subjects: 205